A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX
A Multicenter Clinical Evaluation of the Efficacy and Safety of REGRANEX Gel in the Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Terminated
Slow recruitment; Study did not address safety concern raised by European Medicines Agency
Other terminated trials from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Follicular Lymphoma · Phase PHASE2 · Oct 2011
- Advanced or Refractory Leukemia · Phase PHASE1 · Sep 2011
- Mononeuropathies · Phase PHASE2 · Jul 2011
- Arthralgia · Phase PHASE2 · Jul 2011
- Interstitial Cystitis · Phase PHASE4 · Jun 2011
More terminations from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
This PHASE3 trial investigates Diabetic Foot and Diabetic Neuropathies and is currently terminated or withdrawn. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Dec 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.